Autosomal Dominant Polycystic Kidney Disease (ADPKD) (DBCOND0050861)

Identifiers

Synonyms
Kidney, Polycystic, Autosomal Dominant / Autosomal Dominant Polycystic Kidney / ADPKD / ADPKD (Autosomal Dominant Polycystic Kidney Disease) / Autosomal Dominant Polycystic Kidney Disease (ADPKD / Polycystic Kidney Disease, Autosomal Dominant / Polycystic Kidney, Autosomal Dominant / Autosomal Dominant Polycystic Kidney Disease (ADPKD) / Autosomal Dominant Polycystic Kidney Disease / Polycystic kidney, adult type / Autosomal dominant polycystic kidney disease (disorder) / Congenital cystic kidney disease / Congenital cystic kidney disease (disorder)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Tolvaptan
A selective vasopressin V2-receptor antagonist to slow kidney function decline in patients at risk for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Also used to treat hypervolemic and euvolemic hyponatremia.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT00541853
CCB Safety Study in Treatment of Hypertension of ADPKDtreatment4unknown_status
NCT00890279
Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)treatment2unknown_status
NCT00571909
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain StudyNo drug interventionstreatmentNot Availablecompleted
NCT00784030
High Water Intake to Slow Progression of Polycystic Kidney DiseaseNo drug interventionsbasic_scienceNot Availablecompleted
NCT00067977
Clinical Trial to Slow the Progression of ADPKDNo drug interventionstreatmentNot Availableunknown_status
NCT06391450
Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)treatment4recruiting
NCT04907799
Daily Caloric Restriction in ADPKDNo drug interventionstreatmentNot Availablerecruiting
NCT05228574
Treatment of Vascular Stiffness in ADPKDtreatment4recruiting
NCT06582875
Glucagon-Like Peptide-1 Receptor Agonist in ADPKDtreatment2not_yet_recruiting
NCT05401409
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionstreatmentNot Availablecompleted
NCT03596957
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Diseasetreatment4unknown_status
NCT05500157
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic CystsNo drug interventionstreatmentNot Availablerecruiting
NCT05646420
Thyroid Hormones in ADPKDNo drug interventionspreventionNot Availablecompleted
NCT04111692
A Prospective Observational Study of Foam Sclerotherapy .No drug interventionsNot AvailableNot Availablerecruiting
NCT03918447
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCONtreatment3terminated
NCT03749447
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)treatment3terminated
NCT05478083
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Diseasetreatment2recruiting
NCT03366337
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXtreatment2completed
NCT03102632
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionstreatmentNot Availablecompleted
NCT03203642
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDtreatment2completed
NCT06496542
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKDNo drug interventionstreatmentNot Availablerecruiting
NCT03273413
Statin Therapy in Patients With Early Stage ADPKDtreatment4active_not_recruiting
NCT04310319
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and SaltNo drug interventionstreatmentNot Availableunknown_status
NCT06193616
Outcome of ADPKD With Octreotide LARNot AvailableNot Availablerecruiting
NCT03858439
Dietary Intervention in ADPKD on TolvaptanNo drug interventionstreatmentNot Availablecompleted
NCT05996731
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare DiseasesNo drug interventionsdiagnosticNot Availablerecruiting
NCT04908462
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy VolunteersNo drug interventionstreatment1completed
NCT04064346
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Diseasetreatment3terminated
NCT06100133
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?No drug interventionstreatment2not_yet_recruiting
NCT03764605
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Diseasetreatment3unknown_status
NCT03717883
ADPKD Alterations in Hepatic Transporter FunctionNo drug interventionsNot AvailableNot Availablecompleted
NCT04152837
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Diseasetreatment3terminated
NCT02776241
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsdiagnosticNot Availablecompleted
NCT04472624
Short Term Induction of Ketosis in PKDNo drug interventionsotherNot Availablecompleted
NCT05521191
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionstreatment1recruiting
NCT05373264
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Lifetreatment3not_yet_recruiting
NCT01853553
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)treatment3completed
NCT01632605
The Vienna RAP Pilot StudyNot AvailableNot Availablecompleted
NCT06416761
Genetics in the Progression of NephropathiesNo drug interventionsNot AvailableNot Availablerecruiting
NCT05014178
Kidney Sodium Functional ImagingNo drug interventionsNot AvailableNot Availablerecruiting
NCT06085807
Genetic Testing in Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsNot AvailableNot Availablerecruiting
NCT00345137
Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic GlomerulonephritisNot Available1completed
NCT04338048
Autosomal Dominant Polycystic Kidney Disease (ADPKD) StudyNo drug interventionsNot AvailableNot Availablerecruiting
NCT04680780
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)No drug interventionsotherNot Availablecompleted
NCT02161068
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD GenotypingNo drug interventionsNot AvailableNot Availablecompleted
NCT06618638
Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease TreatmentNo drug interventionstreatmentNot Availablenot_yet_recruiting
NCT02497521
The German ADPKD Tolvaptan Treatment RegistryNo drug interventionsNot AvailableNot Availablerecruiting
NCT06594367
A Possible Founding PKD2 Mutation Associated with Variable Phenotypes of ADPKD in Bergamo ProvinceNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT01214421
Tolvaptan Extension Study in Participants With ADPKDtreatment3completed
NCT02115659
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)treatment3unknown_status
NCT02127437
Lanreotide In Polycystic Kidney Disease Studytreatment3completed
NCT04689074
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney DiseasesNo drug interventionsNot AvailableNot Availablecompleted
NCT06289998
Study of Tamibarotene in Patients With ADPKDtreatment2recruiting
NCT02964273
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)treatment3completed
NCT02925221
Canadian Medical Assessment of JINARC™ Outcomes RegistryNo drug interventionsNot AvailableNot Availablerecruiting
NCT02616055
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101treatment2terminated
NCT02225860
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionstreatment2 / 3completed
NCT02112136
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKDNo drug interventionsdiagnosticNot Availablecompleted
NCT01430494
Observational Study in Patients With Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT00309283
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Studytreatment3completed
NCT03949894
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Diseasetreatment4completed
NCT06345755
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participantstreatment1recruiting
NCT01616927
Study of Lanreotide to Treat Polycystic Kidney Diseasetreatment3unknown_status
NCT01223755
Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiencytreatment2 / 3terminated
NCT00346918
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)treatment3completed
NCT01280721
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]treatment3completed
NCT04536688
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionstreatment1completed
NCT00428948
Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)treatment3completed
NCT03687554
Effect of Venglustat in Patients With Renal Impairmenttreatment1completed
NCT04363554
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsbasic_scienceNot Availablecompleted
NCT03523728
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patientstreatment2 / 3terminated
NCT05510115
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Diseasetreatment2recruiting
NCT03342742
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsotherNot Availablecompleted
NCT02494141
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKDtreatment4completed
NCT02656017
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Diseasetreatment2completed
NCT03803124
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKDbasic_science3completed
NCT01559363
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Diseasetreatment1 / 2completed
NCT02021110
Ursodeoxycholic Acid as Treatment for Polycystic Liver Diseasetreatment2completed
NCT04407481
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)Not AvailableNot Availablecompleted
NCT00426153
Octreotide in Severe Polycystic Liver Diseasetreatment2 / 3completed
NCT00413777
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)treatment2completed
NCT01589705
The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney DiseaseNo drug interventionsNot AvailableNot Availableterminated
NCT00565097
Lanreotide as Treatment of Polycystic Liverstreatment2 / 3completed
NCT02903511
Feasibility Study of Metformin Therapy in ADPKDtreatment2completed
NCT00410007
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsotherNot Availablecompleted
NCT04534985
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsotherNot Availablecompleted
NCT02251275
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Diseasetreatment3completed
NCT02847624
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKDNot AvailableNot Availablecompleted
NCT00456365
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)treatment3completed
NCT01114594
Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT01233869
Bosutinib For Autosomal Dominant Polycystic Kidney Diseasetreatment2completed
NCT04023214
The Role of Endothelial Dysfunction in Adult Polycystic Kidney DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT03493802
Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKDNo drug interventionsNot AvailableNot Availablecompleted
NCT02250287
New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT00598377
Adrenal Functions in Autosomal Dominant Polycystic Kidney DiseasediagnosticNot Availablecompleted
NCT02160145
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Diseasetreatment3completed
NCT05288998
Intrarenal Microvasculature in ADPKDNo drug interventionsNot AvailableNot Availablerecruiting
NCT05870007
Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Diseasetreatment2enrolling_by_invitation
NCT06065852
National Registry of Rare Kidney DiseasesNo drug interventionsNot AvailableNot Availablerecruiting
NCT02119052
Effects of Somatostatin on Liver in ADPKDNo drug interventionstreatment2 / 3completed
NCT02134899
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipientstreatment3completed
NCT03970018
ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure?No drug interventionsNot AvailableNot Availablecompleted
NCT01022424
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]treatment3completed
NCT04284657
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Diseasetreatment2enrolling_by_invitation
NCT01451827
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)treatment2completed
NCT01210560
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKDtreatment2completed
NCT02887729
Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)No drug interventionsNot AvailableNot Availableunknown_status
NCT00414440
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Diseasetreatment4completed
NCT01336972
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)treatment2completed
NCT00841568
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]treatment2completed
NCT02933268
High Water Intake in Polycystic Kidney DiseaseNo drug interventionstreatmentNot Availablecompleted
NCT04344769
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)No drug interventionsNot AvailableNot Availablerecruiting
NCT01377246
Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiencytreatment3completed
NCT05193981
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKDNo drug interventionsNot AvailableNot Availablerecruiting
NCT01810614
A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)No drug interventionspreventionNot Availablecompleted
NCT03901521
Autosomal Dominant Polycystic Kidney Disease Somatic Mutation BiorepositoryNo drug interventionsNot AvailableNot Availableenrolling_by_invitation
NCT02848521
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in EuropeNo drug interventionsNot AvailableNot Availableunknown_status
NCT01039987
Consortium for Radiologic Imaging Studies of Polycystic Kidney DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT03541447
Tolvaptan-Octreotide LAR Combination in ADPKDtreatment2completed
NCT00920309
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapytreatment2 / 3terminated
NCT02322385
Clinical Implications of DNA Analysis on ADPKDNo drug interventionsNot AvailableNot Availablecompleted
NCT02187432
The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across EuropeNo drug interventionsNot AvailableNot Availableunknown_status
NCT02084849
ADPKD Cohort StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT02119013
Effects of Somatostatin on ADPKD HeartNo drug interventionstreatment2 / 3completed
NCT04630613
NOX4 and Related Biomarkers in ADPKDNo drug interventionsNot AvailableNot Availablerecruiting
NCT03487913
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Diseasetreatment2completed
NCT02746419
The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating PainNo drug interventionstreatmentNot Availablewithdrawn
NCT06435858
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Diseasetreatment4not_yet_recruiting
NCT01348035
Efficacy Study of Water Drinking on PKD Progression.No drug interventionsNot AvailableNot Availablecompleted
NCT04939935
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)treatment3recruiting
NCT02527863
Effect of the Aquaretic Tolvaptan on Nitric Oxide Systemtreatment2completed
NCT04578548
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)No drug interventionstreatment2terminated
NCT02729662
Efficacy of Tolvaptan on ADPKD PatientstreatmentNot Availableunknown_status
NCT05190744
PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium AdministrationNo drug interventionssupportive_care2recruiting
NCT05460169
Renal Denervation in ADPKD- RDN-ADPKD StudyNo drug interventionstreatmentNot Availablerecruiting
NCT00759369
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)No drug interventionstreatmentNot Availablecompleted
NCT01670110
Pasireotide LAR in Severe Polycystic Liver Diseasetreatment2completed
NCT01932450
Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression ControlNo drug interventionstreatment2unknown_status
NCT01988038
Repository Study of Autosomal Dominant Polycystic Kidney DiseaseNo drug interventionsNot AvailableNot Availablewithdrawn